Morphea (localized scleroderma)

Meet the patient

A 38-year-old woman notices an oval, waxy, ivory-white patch on her abdomen ringed by a faint lilac border; it is bound down to the skin beneath, has lost its hair, and is slowly enlarging. She has googled "scleroderma" and is terrified of lung and kidney disease. Her hands are warm, her nailfolds are normal, and she has never had Raynaud.^[1][3]

Two questions settle her fear and the whole topic: is this morphea or systemic sclerosis? — the four bedside discriminators answer that, and they are all on her side — and which subtype is it, and is it the kind that deforms a child? Hers is plaque-type, self-limiting and skin-only; the dangerous subtype is linear, and it lives in paediatric rheumatology.^[1][4]

Skin only, never systemic — the four discriminators

Morphea is not systemic sclerosis confined to the skin; it is a biologically distinct regional fibrosis, and four bedside facts prove it. Hold these four and you will never wrongly scare a patient or miss the diagnosis: no Raynaud, normal nailfold capillaroscopy, no internal organ involvement, and negative systemic-sclerosis-specific antibodies (anti-Scl-70/topoisomerase I and anti-centromere).^[1][4]

The biology explains why. In systemic sclerosis a widespread microvasculopathy drives visceral fibrosis — hence Raynaud, nailfold dropout, and lung, gut, renal and cardiac disease. In morphea, regionally dysregulated fibroblasts overproduce collagen in a circumscribed patch (sometimes tracing embryonic Blaschko-line mosaicism, which is why linear disease follows those lines, not dermatomes). There is no systemic vasculopathy, so there is no Raynaud, no nailfold change and no organ fibrosis.^[1][4]

Morphea does not progress to systemic sclerosis, and patients can be told this outright — it is the single most reassuring sentence in the consultation. ANA may be positive in 40-50 percent and anti-histone in about half of linear or generalised disease, but those do not indicate systemic sclerosis; the SSc-specific antibodies stay negative.^[1]

Etymology for viva gold: morphea is from the Greek morphe, "form" or "shape" — a hardened, shaped plaque. En coup de sabre is French for "stroke of a sabre", the vivid image of a depressed paramedian forehead band; Parry-Romberg names the two clinicians who described progressive hemifacial atrophy. Scleroderma itself means hard skin — Greek skleros, hard, plus derma.^[3]

The five subtypes — read the morphology, read the risk

Plaque-type is the prototype — about 80 percent of adult cases — and the one to teach from. The active lesion has three concentric zones: an outer lilac (violaceous) inflammatory ring (the expanding, lymphocyte-rich edge), a central ivory or yellowish indurated zone (sclerotic, bound-down dermis), and eventually atrophy with post-inflammatory hyperpigmentation as the lesion burns out. Over 3-5 years the induration softens to a wrinkled brown patch.^[1][3]

^{[1] [3]}

Linear morphea in a child — the subtype that deforms

Linear morphea is the reason morphea is not always benign: a band of sclerosis crossing a growth plate or a joint can arrest growth and freeze the joint, permanently, in a child. It is the commonest subtype in paediatrics (about two-thirds of childhood cases) and the one that demands early, aggressive systemic therapy rather than watchful waiting.^[1][6]

Two facial variants are heavily examined. En coup de sabre is a depressed, paramedian forehead band, sometimes reaching the scalp (scarring alopecia), cheek or lip, and involving the underlying frontal bone; it carries ipsilateral uveitis (often silent and sight-threatening) and CNS involvement (seizures, headache, intracerebral calcification). Parry-Romberg syndrome is progressive hemifacial atrophy — loss of fat, dermis, muscle and bone — with striking facial and dental asymmetry.^[1][4]

Why it happens — the TGF-beta fibroblast cascade

Morphea is a regional fibrotic reaction: an autoimmune insult lights up dermal fibroblasts to overproduce collagen, and TGF-beta is the conductor. The cascade runs in five linked steps — vascular endothelial injury; a CD4-positive, Th2-skewed (IL-4, IL-13) inflammatory infiltrate at the lilac edge; fibroblast activation through TGF-beta and its Smad 2/3 pathway into myofibroblasts; excess type I and III collagen deposition that engulfs and destroys adnexa; then sclerosis softening into atrophy as the inflammation fades.^[1][4]

The Borrelia burgdorferi question is an exam-worthy curiosity: in some European cohorts (Germany, Austria) serology and lesional PCR have implicated Lyme infection, but the association is absent in UK and North American series and routine antibiotics are not standard outside proven infection. It is a question to know, not a management driver.^[1][3]

How common, who, and the bimodal age

^[1]

Morphea has a characteristic bimodal age distribution: plaque-type peaks in adults aged 20-50, while linear morphea peaks in childhood, roughly 5-10 years. Proposed triggers are mostly local and mechanical — preceding trauma, surgery, radiation therapy (radiation-induced morphea at the treatment field), vaccination and some infections — layered over a familial autoimmune tendency, though morphea itself is largely sporadic.^[1][6]

Face-off — morphea versus systemic sclerosis (and the mimics)

^{[1] [4]}

The classic trap: mislabelling morphea as systemic sclerosis — which provokes needless anxiety and a battery of visceral investigations for a disease the patient does not have. The four discriminators (no Raynaud, normal nailfolds, no organs, negative SSc antibodies) close that question.^[4]

^[4]

Assessment — the lilac ring is the activity, the nailfold is the reassurance

The diagnosis is clinical, confirmed by biopsy when atypical. Examine the lesion for the three concentric zones — active lilac ring, ivory indurated centre, atrophic hyperpigmented periphery — and palpate to confirm it is bound down with lost adnexa (hair loss, reduced sweating). Photograph with a ruler for serial monitoring.^[1]

Exclude systemic sclerosis at the bedside. Examine the hands for sclerodactyly, digital pitting and ischaemic ulcers (all absent in morphea); perform nailfold capillaroscopy with immersion oil and a dermatoscope — normal regular loops in morphea, giant capillaries and dropout in systemic sclerosis; and ask explicitly about Raynaud.^[4]

Stage subtype and activity. Decide plaque, linear, generalised, bullous or deep, and whether lesions are active (lilac edge, warmth, expansion) or burnt out (atrophic, hyperpigmented). The modified Localized Scleroderma Skin Severity Index (mLoSSI) grades activity across three domains — new lesion or extension, erythema, skin thickness, each 0-3; a rising mLoSSI means active, treatable disease, a flat one with high LoSDI means burnt-out disease that will not respond to systemic therapy.^[9]

In linear disease, measure limb length and circumference and joint range of motion at every visit for growth surveillance; in facial disease, assess symmetry, lid position and ocular motility, and arrange ophthalmology (silent uveitis) and neurology with imaging if there are seizures, headache or focal signs.^[1][6]

Investigations — histology when unclear, antibodies to exclude SSc

Histology of the active lilac edge shows thickened, homogenised (hyalinised) collagen bundles in the reticular dermis, loss of adnexal structures (hair follicles, sweat glands engulfed and destroyed) and a lymphocytic infiltrate at the active border — early lesions more inflammatory, late lesions densely sclerotic with little inflammation. Dermoscopy can support recognition but biopsy is the answer when morphology is atypical.^[1][10]

Laboratory: ANA positive in 40-50 percent (more often in linear and generalised) but not indicating SSc; anti-histone in about half of linear or generalised morphea; anti-Scl-70 and anti-centromere negative — their presence argues for systemic sclerosis. Baseline FBC, electrolytes, liver and renal function and inflammatory markers screen for overlapping autoimmune disease and provide a baseline before systemic therapy. Borrelia serology and PCR only in European endemic regions with a suggestive history.^[1][3]

Imaging and monitoring: clinical photography (the single most useful tool), infrared thermography (a hot lilac edge is active, a cooling one is burning out), 20 MHz ultrasound (objective dermal thickness), and MRI for suspected deep or subfascial involvement and for facial disease to assess bone, muscle and intracranial change.^[1]

Management — match the subtype and the activity, not the label

There is no cure, and the Cochrane review found the evidence thin — so therapy is stratified by subtype and activity, and the central principle is a fork: burnt-out plaque disease needs little; active linear disease in a child needs methotrexate now.^[1][5]

Step 1 — topical therapy for limited plaque-type disease. The S2k guideline recommends a topical corticosteroid as primary therapy for limited skin involvement; UV therapy is an additional option.^[1][11] A systematic review of the treatment literature supports topical calcipotriene and topical tacrolimus for limited superficial inflammatory lesions.^[12]

Step 2 — phototherapy for widespread superficial plaque-type. In the Cochrane review's head-to-head randomised comparison, medium-dose UVA1 (50 J/cm2), low-dose UVA1 (20 J/cm2) and narrowband UVB showed little or no difference in global improvement of disease activity or damage; the trials treated active morphea five times weekly for eight weeks.^[5] Narrowband UVB causes less mild tanning than UVA1.^[5]

Step 3 — systemic therapy for active linear, generalised or deep disease. Corticosteroids plus methotrexate are the mainstay.^[1] In the Cochrane review's key randomised trial, children and adolescents with active morphea received oral methotrexate 15 mg/m2 (maximum 20 mg) once weekly for 12 months or until flare, plus oral prednisone 1 mg/kg/day (maximum 50 mg) in a single morning dose for three months with a one-month taper; global improvement was more likely than with placebo plus prednisone (RR 2.31, 95 percent CI 1.20 to 4.45; NNTB 3).^[5] A single-centre paediatric protocol used oral prednisone 2 mg/kg/day (maximum 60 mg/day) tapered to 0.25 mg/kg/day and continued for 12 months, with subcutaneous methotrexate 1 mg/kg/week (maximum 25 mg/week) continued for 24 months before switching to oral to complete 36 months.^[7] In methotrexate-refractory or intolerant juvenile localized scleroderma, mycophenolate mofetil is the established second-line agent; after a mean of 9.4 years of follow-up, 90.9 percent of MMF-treated patients had inactive disease.^[8]

^{[5] [7] [8]}

Step 4 — physiotherapy and reconstruction. Physiotherapy and occupational therapy are essential in linear disease crossing joints to prevent and treat contractures. Reconstructive surgery — tissue expansion, autologous fat grafting, scar revision, orthognathic correction — is undertaken only after the disease has been inactive for 1-2 years, because operating on active morphea risks reactivating the fibrosis.^[1]

Throughout treatment, monitor with mLoSSI, serial photography, infrared thermography and (in children) limb length, circumference and joint range of motion; maintain ophthalmology surveillance in facial disease and arrange neuroimaging if neurological symptoms arise. Reassure the patient at every visit that morphea does not progress to systemic sclerosis.^[1][6]

How patients with morphea come to harm (the preventable list)

• Linear disease under-treated in a growing child — permanent limb length discrepancy, joint contracture, facial asymmetry that methotrexate started earlier could have prevented^[1][6]
• Silent uveitis in en coup de sabre missed — sight-threatening because no one did a baseline ophthalmology review^[1]
• CNS involvement in en coup de sabre written off as headache — seizures and intracerebral calcification missed without neuroimaging^[1]
• Mislabelling as systemic sclerosis — needless terror and a battery of visceral investigations for a disease the patient does not have^[4]
• Treating burnt-out plaque-type disease aggressively — systemic agents cannot reverse established atrophy; the mLoSSI and thermography would have shown it was inactive^[9]
• Methotrexate in pregnancy — teratogenic; stop at least three months before conception in women and men^[1]
• Reconstructive surgery during active disease — reactivating and worsening the fibrosis; wait 1-2 years of inactivity^[1]

Special populations

Children (juvenile localized scleroderma): in the largest Indian single-centre cohort, linear scleroderma was the commonest subtype (57 of 84 patients, 67.7 percent), median age at onset 5 years, and 72.6 percent received methotrexate; the authors conclude that early systemic corticosteroids alongside methotrexate may be more beneficial than methotrexate alone.^[13] Paediatric disease runs a more severe course than adult-onset disease: extracutaneous involvement is twice as prevalent in linear scleroderma, relapses are more common, and disease duration is more than double.^[14] Methotrexate is recommended for linear, deep and generalised subtypes, continued for at least 12 months after an adequate response; physiotherapy and psychological support sit alongside drug therapy, and surgery waits for inactivity.^[10]

Pregnancy: methotrexate is absolutely contraindicated — stop at least three months before conception in both sexes. Transition active disease to pregnancy-safe topical therapy and phototherapy under specialist guidance. Morphea itself does not appear to harm fertility or pregnancy and often improves during pregnancy.^[1]

Cosmetic and psychological burden: adults with facial or extensive plaque-type disease carry a significant burden of atrophy and hyperpigmentation; camouflage cosmetics, psychological support and — once disease is inactive — reconstructive and laser techniques all have a role.^[1]

Prognosis and disposition

Plaque-type morphea is self-limiting, each lesion evolving through inflammation to sclerosis to atrophy over about 3-5 years and leaving a brown atrophic patch; there is no mortality. Linear morphea is progressive in children and can cause permanent deformity if untreated, but early aggressive methotrexate plus corticosteroids substantially improves outcome — residual deformity may still need later reconstructive surgery. The reassurance examiners reward: morphea does not progress to systemic sclerosis.^[1][3]

Limited plaque-type disease is managed in dermatology outpatients with topical therapy and phototherapy; linear, generalised, deep and all juvenile disease need a multidisciplinary team — dermatology and paediatric rheumatology, physiotherapy and occupational therapy, ophthalmology for facial disease, and neurology and maxillofacial surgery where indicated. Admission is rarely needed; the urgency is the timely start of systemic therapy for active linear disease in a child.^[1][6]

The mantra, and the memory device

^[1]

The mantra: skin only, never systemic; four discriminators from systemic sclerosis; plaque-type self-limiting, linear in a child needs methotrexate now; and never operate on active disease.^[1][4]

Ward-round test — three stems, thirty seconds each

Stem 1 — the ivory plaque and the terrified patient (answer)ShowHide

A 38-year-old woman has an oval ivory, bound-down plaque with a lilac ring on her abdomen; no Raynaud, normal nailfolds, no systemic symptoms. What is it, and what do you tell her? Model: Plaque-type morphea, classic three-zone morphology. Confirm clinically (biopsy only if atypical), exclude systemic sclerosis with the four discriminators (no Raynaud, normal nailfold capillaroscopy, no organ involvement, negative anti-Scl-70 and anti-centromere), and reassure her on the point she fears most: morphea does not progress to systemic sclerosis. Treat with a short course of super-potent topical clobetasol to settle the lilac edge, with calcipotriol or phototherapy if widespread. Set the expectation of a self-limiting 3-5 year course leaving a brown atrophic patch.^[1][4]

Stem 2 — the sabre cut on a child's forehead (answer)ShowHide

A 7-year-old girl has a depressed linear band on her paramedian forehead and a shorter indurated band crossing her right elbow. What subtype is this, what are the risks, and what is first-line management? Model: Linear morphea with en coup de sabre. The risks are permanent — joint contracture and growth arrest at the elbow, limb length discrepancy, facial asymmetry — plus extracutaneous problems: in a paediatric craniofacial scleroderma series, neuroimaging was abnormal in 25 of 73 children imaged, with headaches or seizures in about half of those, and lesions ipsilateral to the skin findings in 88 percent.^[15] First-line is methotrexate plus a corticosteroid bridge — the juvenile trial regimen is oral methotrexate 15 mg/m2 weekly (maximum 20 mg) for 12 months with prednisone 1 mg/kg/day (maximum 50 mg) for three months then tapered^[5] — alongside physiotherapy, baseline ophthalmology review, and neuroimaging when neurological symptoms arise. Reconstructive surgery waits until the disease has been inactive. Watchful waiting is the error.^[1][10]

Stem 3 — is this systemic sclerosis? (answer)ShowHide

A 45-year-old with tight, shiny fingers, Raynaud, digital pitting scars and abnormal nailfold capillaries has an ANA and anti-Scl-70 positive. Is this morphea? Model: No — this is systemic sclerosis, and the discriminators are all against morphea: symmetric distal-to-proximal sclerodactyly, Raynaud present, abnormal nailfold capillaroscopy with giant capillaries and dropout, and anti-Scl-70 positive (morphea is anti-Scl-70 and anti-centromere negative). The management forks completely — systemic sclerosis needs visceral screening (lung function and HRCT for ILD, echocardiogram, renal surveillance), vasodilators and immunosuppression for organ-threatening disease, none of which belong in morphea. Mislabelling this as morphea would miss life-threatening internal disease.^[1][4]

References15ShowHide

1. [1]Papara C, De Luca DA, Bieber K, Vorobyev A, et al. Morphea: The 2023 update Front Med (Lausanne), 2023.PMID 36860340
2. [2]Wenzel D, Haddadi NS, Afshari K, Richmond JM, et al. Upcoming treatments for morphea Immun Inflamm Dis, 2021.PMID 34272836
3. [3]Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update An Bras Dermatol, 2015.PMID 25672301
4. [4]Ferreli C, Gasparini G, Parodi A, et al. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review Clin Rev Allergy Immunol, 2017.PMID 28712039
5. [5]Albuquerque JVG, Andriolo BN, Vasconcellos MR, Civile VT, et al. Interventions for morphea Cochrane Database Syst Rev, 2019.PMID 31309547
6. [6]Kaushik A, Mahajan R, De D, Handa S. Paediatric morphoea: a holistic review. Part 2: diagnosis, measures of disease activity, management and natural history Clin Exp Dermatol, 2020.PMID 32449205
7. [7]Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study J Rheumatol, 2012.PMID 22247357
8. [8]Martini G, Saggioro L, Culpo R, et al. Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma Rheumatology (Oxford), 2021.PMID 32978631
9. [9]Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study Rheumatology (Oxford), 2010.PMID 20008472
10. [10]Errichetti E, Stinco G. Dermoscopy in General Dermatology: A Practical Overview Dermatol Ther (Heidelb), 2016.PMID 27613297
11. [11]Kreuter A, Moinzadeh P, Kinberger M, Horneff G, et al. S2k guideline: Diagnosis and therapy of localized scleroderma J Dtsch Dermatol Ges, 2024.PMID 38426689
12. [12]Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm J Am Acad Dermatol, 2011.PMID 21645943
13. [13]Jindal AK, Handa S, Loganathan SK, Sudhakar M, et al. Juvenile localized scleroderma: A single-centre experience from India J Eur Acad Dermatol Venereol, 2023.PMID 36413107
14. [14]Vasquez-Canizares N, Li SC. Juvenile Localized Scleroderma: Updates and Differences from Adult-Onset Disease Rheum Dis Clin North Am, 2021.PMID 34635302
15. [15]Seese RR, Glaser D, Furtado A, Thakkar K, et al. Unilateral Neuroimaging Findings in Pediatric Craniofacial Scleroderma: Parry-Romberg Syndrome and En Coup de Sabre J Child Neurol, 2020.PMID 32527172